The FDA this week approved Janssen’s Invokana for a new indication, to prevent kidney disfunction and reduce the risk of developing end-stage kidney disease in type 2 diabetes patients. Invokana is the first drug to be approved for this indication almost 20 years. For the treatment of type 2 diabetes, Invokana holds preferred formulary status for 28% of covered lives, growing to 50% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 10/2/19